2. Emergency Use Authorization (EUA) for COVID-19 Drug Nirmatrelvir 150 mg Film-Coated Tablet + Ritonavir 100 mg Film-Coated Tablet (Co-Packaged in Alu/Alu Push-Through Blister Pack) [PAXLOVID]. FDA, 10 March 2022. 3. FACT ...
Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid (PDF) (Technical report). Pfizer. 22 December 2021. LAB-1492-0.8. Archived from the original on 23 December 2021. "Paxlovid EPAR". European Medicines Agency (EMA...
2. Emergency Use Authorization (EUA) for COVID-19 Drug Nirmatrelvir 150 mg Film-Coated Tablet + Ritonavir 100 mg Film-Coated Tablet (Co-Packaged in Alu/Alu Push-Through Blister Pack) [PAXLOVID]. FDA, 10 March 2022. 3. FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR ...
参考文献 [1] Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid, FDA. [2]https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html [3]https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care /underlyingconditions.html ...
[1] Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid, FDA. [2]https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html [3]https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care /underlyingconditions.html ...
[5]Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid, FDA. [6]https://mp.weixin.qq.com/s/PPpUfHXyrXmw-NE_z4tozg [7]Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers, FDA. [8]中国医师协会肝癌专业委员会. 肝细胞癌分子靶向药物临床应用中国专家共...
FDA. Fact sheet for healthcare providers:emergency use authorization for paxlovid[EB/OL].(2021-12-12). https://www.fda.gov/media/155050/download. https://www.fda.gov/media/155050/download 本文引用 [1] [4] FDA. Fact sheet for patients,parents,and caregivers emer-gency use authorization...
[1] Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid, FDA. [2]https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html [3]https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care /underlyingconditions.html ...
参考资料:1.Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. 2.Fact Sheet for Healthcare Providers - FDA. Paxlovid在全球多个国家已上市,海外药品上市情况,海外原研药/仿制药价格等,欢迎咨询海得康。
PAXLOVID is not recommended for use in patients with severe hepatic impairment. Please see Fact Sheet for Healthcare Providers and Fact Sheet for Patients, Parents, and Caregivers Looking for information about the FDA-approved indication for PAXLOVIDTM (nirmatrelvir tablets; ritonavir tablets)? Go...